Impact of deucravacitinib on NLR and other inflammatory biomarkers of cardiovascular risk in psoriasis: Posthoc analyses of phase 3 trials
Abstract
Psoriasis is a chronic inflammatory disease linked to heightened systemic inflammation and increased cardiovascular (CV) morbidity and mortality (Svedbom et al., 2025). Systemic inflammatory biomarkers, including neutrophil-to-lymphocyte ratio (NLR), high-sensitivity C-reactive protein (hs-CRP), and platelet-to-lymphocyte ratio (PLR), are associated with future CV risk and all-cause mortality (Adamstein et al., 2021). Reduction of NLR and hs-CRP by canakinumab was associated with reduced recurrent cardiovascular events in patients with prior myocardial infarction and high hs-CRP (Ridker et al., 2017).
Fields of Study & Subjects
Psoriasis: Treatment and Pathogenesis
Inflammasome and immune disorders
Spondyloarthritis Studies and Treatments
Publication details
- Journal / source
- Journal of Investigative Dermatology
- Publisher
- Elsevier BV
- Volume
- 146
- Issue
- 9
- Pages
- 2598–2602.e2
- Publication date
- 25 February 2026
- Language
- EN